United Kingdom

Acacia Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Acacia Pharma Proposed Capital Raising by Way of a Placing of New Ordinary Shares and Provides Update on Early Launch of BARHEMSYS®

Lead Product(s): Amisulpride

Therapeutic Area: Gastroenterology Product Name: Barhemsys

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $23.5 million Upfront Cash: Undisclosed

Deal Type: Financing February 18, 2021

Details:

The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference and speaker programs.

Acacia Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Acacia Pharma Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS® and BYFAV...

Lead Product(s): Amisulpride

Therapeutic Area: Gastroenterology Product Name: Barhemsys

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing October 09, 2020

Details:

The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.